Zymeworks, Inc.

281 articles about Zymeworks, Inc.

• Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

  1/4/2023

  Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.

• 

  Jazz Doubles Down on Zymeworks' Bispecific HER2 Candidate Zanidatamab (Updated)

  12/21/2022

  Jazz Pharmaceuticals exercised its option on Zymeworks' promising anti-cancer agent.

• Zymeworks Announces Participation in Upcoming Investor Conference - December 21, 2022

  12/21/2022

  Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

• Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

  12/21/2022

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab.

• Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

  12/19/2022

  Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab.

• Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

  12/14/2022

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium.

• New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

  12/9/2022

  Zymeworks Inc. (NYSE: ZYME) today presented new clinical data for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor degrader, in patients with heavily pretreated HER2-positive hormone-receptor positive metastatic breast cancer.

• Zymeworks to Transfer Stock Listing to Nasdaq - December 05, 2022

  12/5/2022

  Zymeworks Inc. announced that it has elected to transfer its stock exchange listing from the New York Stock Exchange to The Nasdaq Stock Market LLC, where the vast majority of its biotechnology peer companies also trade.

• Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals

  11/29/2022

  Zymeworks Inc. today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals has expired.

• Zymeworks Announces Participation in Upcoming Investor Conference - November 22, 2022

  11/22/2022

  Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

• Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

  11/21/2022

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody.

• Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results

  11/8/2022

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2022.

• Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms

  10/20/2022

  Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the highlights from its early R&D Day reviewing the Company’s progress and plans for the development of its novel pipeline assets and applications of its proprietary next-generation technology platforms.

• Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab

  10/19/2022

  Zymeworks Inc. announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks’ proprietary Azymetric™ platform, with Jazz Pharmaceuticals plc.

• Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

  10/19/2022

  Jazz Pharmaceuticals plc and Zymeworks Inc. announced that Jazz and Zymeworks' subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.

• 

  Jazz Drops $50M for Exclusive Rights to Zymeworks’ Bispecific HER2 Hopeful

  10/19/2022

  ​​​​​​​Jazz and Zymeworks entered into a $50 million licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2.

• Zymeworks to Host Third Quarter Results Conference Call

  10/18/2022

  Zymeworks Inc. today announced that management will report its third quarter 2022 financial results after market close on November 8th , 2022.

• Zymeworks Completes Plan to Become Delaware Corporation

  10/13/2022

  Zymeworks Inc. today announced the completion of its previously announced intention to complete a series of transactions (the “Redomicile Transactions”), resulting in the following: (i) Zymeworks Delaware Inc. (renamed as Zymeworks Inc.) (“New Zymeworks”) becoming the ultimate parent company incorporated in Delaware.

• Zymeworks Announces Results of Special Meeting

  10/7/2022

  Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME) is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware corporation (the “Redomicile”) at the special meeting of Zymeworks securityholders (the “Special Meeting”) held in Vancouver, BC, on October 7, 2022.

• Zymeworks Reminds Shareholders to Vote FOR its Redomicile

  10/4/2022

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reminds shareholders that the deadline for voting FOR the Company’s plan to become a Delaware corporation is 9:00 a.m., Pacific Time, on October 5, 2022.